Akèy › Myelom Miltip › Alabama
Etid klinik pou Myelom Miltip nan Alabama
22 etid pou Myelom Miltip ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04634552A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06980480A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06988488MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 18, 2026 · NCT06153251Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT07333261Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 31, 2025 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
Ap rekrite
Laj 60 ak plis · Tout sèks · Mizajou Dec 24, 2025 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Dec 8, 2025 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 5, 2025 · NCT05372354Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.